โ† All deals

GLAUKOS Corp

Public Equity (NYSE)Medical DevicesOphthalmologyPublic Company
๐Ÿ“ Aliso Viejo, CA, United Statesโ€ข Founded 1998
StreetZero Signal 57
Be the first to signal interest

About GLAUKOS Corp

Glaukos Corporation is a public ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Founded in 1998 and headquartered in Aliso Viejo, CA, it operates a B2B business model in the Medical Equipment Manufacturing industry. The company completed its IPO on the NYSE in June 2015 under ticker GKOS and continues to develop and commercialize products such as intracameral procedural pharmaceuticals and corneal cross-linking therapies.

LATEST FUNDINGRule 144
$215K
Announced 2026-11-16
TOTAL RAISED$182.20M
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for GLAUKOS Corp.

Free plan includes 3 full deal profiles every month.

EMPLOYEESโ€”
FOUNDED1998
HQAliso Viejo, CA, United States
Industry
Public Equity (NYSE)
Tags
Medical DevicesOphthalmologyPublic CompanyGlaucoma

Key highlights

  • Completed IPO in June 2015 on NYSE at $18 per share with full exercise of underwriter option.
  • Raised total of $118M-$182M over 10 rounds prior to going public.
  • Develops long-duration intracameral pharmaceuticals and FDA-approved corneal cross-linking therapies.
  • Celebrated 10th anniversary of NYSE listing in June 2025.
  • Q3 revenue reached $211M with strong growth in glaucoma and corneal franchises.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account